Your trusted source for the latest news and insights on Markets, Economy, Companies, Money, and Personal Finance.

Invest in Healthcare Stocks During an Economic Downturn

Key Points

  • Healthcare stocks tend to perform well during economic downturns due to stable demand.
  • Low inflation benefits healthcare companies by slashing price pressures, helping them maintain profitability and dividend payments.
  • Despite trailing some growth sectors, healthcare stocks offer stability combined with potential for growth.
  • 5 stocks we like better than AbbVie

If you’re looking for a sector that’s on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.

The top components within the sector are Eli Lilly & Co. NYSE: LLY, Johnson & Johnson NYSE: JNJ, UnitedHealth Group Inc. NYSE: UNH, Merck & Co. Inc. NYSE: MRK and AbbVie Inc. NYSE: ABBV.

None of those stocks are in crash-and-burn mode, but all are trading below their highs.

Healthcare stocks tend to outperform others during economic downturns or periods of sluggish activity for several reasons. That’s important, as many analysts are forecasting slower economic activity in the fourth quarter.

Demand for healthcare services remains relatively stable regardless of economic conditions, as people continue to require medical care.

Reliable Revenue Streams

Typically, people continue refilling prescriptions and receiving necessary treatments even when the economy slumps.

In addition, healthcare companies often produce essential items such as medications and medical devices, ensuring consistent revenue streams.

That means healthcare companies have some defensive qualities, making them attractive to investors seeking stability.

For example, in 2022, healthcare declined only 2%, holding up far better than most sectors, trailing only red-hot energy, dividend hero utilities and defensive safe haven consumer staples.

In addition to performing better during economic pullbacks, healthcare stocks also tend to do well when inflation eases, which analysts expect to happen in the coming months.

Low inflation typically translates to reduced price pressures on healthcare companies, meaning they can better manage their own expenses. This helps the companies maintain profitability and continue their dividend payments or even increase shareholder payouts.

Lagging Growth Sectors in 2023

The top-performing healthcare stock in the past three months is Eli Lilly, followed by , , and AbbVie.

The healthcare sector ETF has a dividend yield of 1.6%, meaning price declines are partially offset by those shareholder payouts.

As a whole, healthcare, which includes sub-industries such as biotech and biomedicine, is on the cutting edge of technological advancement.

Smaller Healthcare Stocks: Risk and Return Equation

Many of those companies at the forefront of tech, such as , are mid-caps or small-caps. That means they carry more risk, especially as many of those smaller company stocks get whipsawed due to clinical trial results or regulatory actions.

Even among some of the large-cap healthcare stocks, new products can catch on quickly and send shares into rally mode. For example, Novo Nordisk A/S NYSE: NVO and Eli Lilly advanced in recent months on strong sales of weight-loss drugs.

The industry is also reliant on constant growth. As existing treatments lose patent exclusivity, meaning they can be manufactured generically, pharmaceutical companies have to launch new products with robust revenue potential.

Fertile Ground for M&A Activity

The industry depends on merger and acquisition activity for that reason. Larger pharmaceutical companies frequently purchase small biotechs with a promising treatment, which benefits investors in the company being acquired.

For example, in March, Pfizer Inc. NYSE: PFE said it would acquire Seagen Inc. NASDAQ: SGEN, a biotech that makes cancer treatments, for $43 billion. Assuming it gets the nod from regulators, it would be the largest biopharma deal in three years. It’s expected to close later this year or early next year.

Pfizer’s offer values Seagen shares at $229 apiece, a premium to where Seagen is currently trading.

While no sector is immune to sharp downturns, healthcare has some factors that make it more resilient than others when economic conditions change.

While it has elements of growth, as you can see by the rapid development of technologies in the biotech sector, it also has elements of an income-generating sector, as many long-established companies are dividend payers.

Before you consider AbbVie, you’ll want to hear this.

financehubusa keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. financehubusa has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and AbbVie wasn’t on the list.

While AbbVie currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Share this article
Shareable URL
Prev Post

Becoming Increasingly Expensive The Cost of Housing is Rising in Certain Areas of the United States

Next Post

Has Etsy’s Upgrade and $100 Target Price Marked the Bottom of the Market?

Leave a Reply

Your email address will not be published. Required fields are marked *

Read next
Key Factors Shares have been consolidating after taking a dive after their newest earnings.  Nonetheless, the…
Key Factors Bears determined to ditch their views on this one ETF, which immediately requires a brand new set of…
Key Factors Pure Storage inventory is shifting larger after the corporate delivered a strong earnings report…
Key Factors Jabil Inc. had a weak quarter following the sale of its mobility enterprise, however margin and…